Medicure announces new partnership through Marley Drug

See Press Release

Research and Products

FDA Provides Complete Approval to Enroll Patients in its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Medicure's Phase 3 clinical trial aims to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.

Learn More

Medicure Reports Financial Results for Quarter Ended September 30, 2023

A conference call was held on Wednesday November 22, 2023. See the full press release.

Learn More

Medicure Aims to Improve Access to Zypitamag (pitavastatin) for people living with HIV

Learn more

Interview on Medicure's 25th Anniversary with CEO, Dr. Albert Friesen

Read More

Medicure Launches E-Commerce Pharmacy Platform Through its Subsidiary Marley Drug Pharmacy

Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.

Learn More

Lipid management is important for heart health

At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.

Learn More

News and Media

Antiplatelet therapy in the management of stroke patients

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage

Learn More